

Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Barlogie-Salmon Myeloma Committee

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Amrita Y. Krishnan, MD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair:.....Jing Christine Ye, MD, MSc
 Executive Officer Alex Herrera, MD
 Statisticians:Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation:Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging:.....Eric M. Rohren, MD, PhD
 Pathology:..... Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

NCORP Representative:.....Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals: Brandon Richard Labadie, CCRP
 Patient Advocate:..... Paul Gater, MPhil
 Pharmaceutical Science:..... Craig Elg, PharmD
Yumena Kawasaki, PharmD
 Protocol Project Manager:..... Amy Doyle
 Clinical Trials Program Manager:.....Sharon Palmer

Time/Location

Friday, May 1, 2026 4:30 p.m. - 6:30 p.m.
 Room: Pacific HI (Pacific Concourse Level)

Agenda

Welcome & Introductions Amrita Krishnan, MD
Active Trials Updates Sikander Ailawadhi, MD
 Patrick Hagen, MD
 Amrita Krishnan, MD
Trials in Development Brea Lipe, MD
 Sikander Ailawadhi, MD
 Hira Mian, MD, FRCPC

Keynote Speaker:

Jonathan Keats, PhD
 Associate Professor, Cancer Genomics and Therapeutics Division Director
 of Bioinformatics and Collaborative Sequencing Center Scientific Director,
 Judy and Bernard Briskin Center for Multiple Myeloma Research
 Translational Genomics Research Institute, part of City of Hope

TM Subcommittee Update J. Christine Ye, MD, MSc

Completed Studies and Other Cooperative Group Trials

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/8/22; Re-activated: 2/15/24. Temporarily closed: 11/21/25.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 5/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/1/23.

A062102, "Randomized Phase II Study of Ibrutinib Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 4/4/24.

EEA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. M. Butler. Activated: 4/30/19.

EEA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.

Barlogie-Salmon Myeloma Committee

Developing Studies

S2508, “A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM).” Drs. B. Lipe, J.C. Ye, and A. Cowan.

S2604, “A Phase III Study for Evaluation of Maintenance Cessation in Patients with Standard Risk Myeloma Achieving Minimal Residual Disease Negativity.” Dr. M. Mohyuddin.

Closed Studies

S1803, “Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study).” Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, “A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM).” Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, “A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis.” Drs. T. Parker and V. Sanchorawala. Activated: 3/8/18; Closed: 9/30/19.

S1304, “A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma.” Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15; Complete: 1/17/25.

S0777, “Frontline Phase III Rev/Dex +/- Vel, no upfront transplant.” Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, “A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders.” Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, “Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy.” Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, “Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone.” Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).” Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), “High-risk AMM – Revlimid.” Dr. M. Dhodapkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, “Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone.” Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

EAA171, “Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM).” Dr. S. Kumar. Activated: 6/1/21. Closed 3/3/23.

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1702 Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). T Parker, A Rosenthal, V Sanchorawala, H Landau, E Campagnaro, P Kapoor, N Neparidze, S Girnius, P Hagen, E Scott, A Hoering, B Durie, R Orlowski. *Blood* Sep 9;blood.2024027962, 2025. <https://pubmed.ncbi.nlm.nih.gov/40925099/>

Submitted Manuscripts

Interim Analysis in Clinical Trials: Caution Against Premature Conclusions – The SWOG Multiple Myeloma S0777 Case Study. Goren E, Sexton R, Orlowski R, Hoering A. Submitted 2025.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1803	S2005	S2209	S2213	EAA173	EAA181
AdventHealth Parker	2	-	-	-	-	-
Banner University Medical Center - Tucson	12	-	-	-	-	5
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	2	-	-	-
Boston Medical Center	5	-	-	3	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	1	1	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-
Carolinas Medical Center/Levine Cancer Institute	23	1	-	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	5	-	-	-
Columbia University Minority Underserved NCORP	-	-	1	4	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	3	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	7	-	-	-	9	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-
Georgia NCI Community Oncology Research Program	21	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-
Heartland Cancer Research NCORP	12	-	5	-	-	-
Henry Ford Hospital	2	1	-	-	4	2
Houston Methodist Hospital	13	-	-	1	-	-
Intermountain Medical Center	-	1	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	60	-	9	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	4	-	-	-
Lahey Hospital and Medical Center	3	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	3	4
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Info Center	-	-	1	-	-	2
Medical University of So Carolina Minority Underserved NCORP	60	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	13	-	2	-	-	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1803	S2005	S2209	S2213	EAA173	EAA181
Moffitt Cancer Center	48	-	-	-	-	-
Montana Cancer Consortium NCORP	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	4	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	15	-	5	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	3	9
Pacific Cancer Research Consortium NCORP	18	-	7	1	-	-
Regents of the University of Michigan	16	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	3	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-
UC Davis Comprehensive Cancer Center LAPS	27	-	7	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	19	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	5	-	-	5
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	1	-	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	1	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	3	-	-	-
University of Rochester LAPS	15	2	2	-	-	6
University of Texas MD Anderson Cancer Center LAPS	27	-	4	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	4	2
Upstate Carolina Consortium Comm Oncology Research Program	4	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	18	-	2	1	-	-
Wisconsin NCI Community Oncology Research Program	23	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5	1	4	8
ALLIANCE	226	4	12	6	-	-
CCTG	21	-	-	-	-	-
ECOG-ACRIN	188	12	10	4	-	-
NRG	117	1	5	2	-	-
Total	1,338	22	111	30	39	46

